Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction
Primary Purpose
Klatskin's Tumor
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Photodynamic therapy using polyhematoporphyrin
Sponsored by
About this trial
This is an interventional treatment trial for Klatskin's Tumor focused on measuring Photodynamic therapy
Eligibility Criteria
Inclusion Criteria:
- Undergone photodynamic therapy as a treatment for malignant biliary obstruction.
Exclusion Criteria:
- None
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Photodynamic therapy
Arm Description
Patients who underwent photodynamic therapy for malignant biliary obstruction.
Outcomes
Primary Outcome Measures
Safety of photodynamic therapy
Treatment emergent adverse events
Secondary Outcome Measures
Efficacy of photodynamic therapy
Overall survival as surrogate marker of treatment efficacy
Full Information
NCT ID
NCT02504957
First Posted
July 19, 2015
Last Updated
October 23, 2015
Sponsor
Medical University of Vienna
1. Study Identification
Unique Protocol Identification Number
NCT02504957
Brief Title
Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction
Official Title
Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction - a Retrospective Analysis.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
July 2015 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
August 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Photodynamic therapy (PDT) is a palliative treatment for malignant biliary obstruction. The aim of this study is to assess the feasibility and safety of this technique in the context of a nationwide retrospective analysis.
Detailed Description
INTRODUCTION
Malignant biliary obstruction is a life threatening condition in patients suffering from primary or secondary bile duct malignancies. Palliative therapies aim to prevent complications associated with the obstruction. Photodynamic therapy (PDT) aims to reduce the local tumor mass by inducing tumor necrosis after light activation of a photosensitizer during endoscopic retrograde cholangiography (ERC).
STUDY AIMS
The aim of the present study is to evaluate the feasibility and safety of PDT with polyhematoporphyrin, the photosensitizer most commonly used for PDT in Austria, in the context of a nationwide analysis.
METHODS
This retrospective study will be conducted at seven Austrian referral centers for bilio-pancreatic endoscopy. The study protocol was approved by the internal review board of the Medical University of Vienna (EK 1448/2012). Patients who underwent PDT with polyhematoporphyrin as therapy for malignant biliary obstruction after 2004 will be identified using examination report databases. Examination reports and patient charts will be analyzed to assess underlying diseases, oncological co-therapies, intra-procedural adverse events, hospital stay, adverse events within 30 days post intervention as well as 30-day, 90-day, and overall mortality. All patient data will be de-identified using pseudonymization prior to any further processing. Descriptive statistics will be used to present the study parameters. Survival will be assessed using Kaplan-Meier statistics and compared between the different underlying tumor entities using the Log Rank test. Cox regression will be used to identify independent predictors of survival. Significant factors at univariate analysis will be entered into multivariate testing. P-values less than 0.05 will be considered significant. SPSS version 23.0 will serve for data analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Klatskin's Tumor
Keywords
Photodynamic therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
88 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Photodynamic therapy
Arm Type
Other
Arm Description
Patients who underwent photodynamic therapy for malignant biliary obstruction.
Intervention Type
Procedure
Intervention Name(s)
Photodynamic therapy using polyhematoporphyrin
Primary Outcome Measure Information:
Title
Safety of photodynamic therapy
Description
Treatment emergent adverse events
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Efficacy of photodynamic therapy
Description
Overall survival as surrogate marker of treatment efficacy
Time Frame
From date of first photodynamic therapy until date of death from any cause, assessed up to 100 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Undergone photodynamic therapy as a treatment for malignant biliary obstruction.
Exclusion Criteria:
None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Werner Dolak, M.D.
Organizational Affiliation
Medical University of Vienna
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
10536130
Citation
de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999 Oct 28;341(18):1368-78. doi: 10.1056/NEJM199910283411807. No abstract available.
Results Reference
background
PubMed Identifier
9496944
Citation
Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Muller JM, Hortnagl H, Lochs H. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998 Mar;114(3):536-42. doi: 10.1016/s0016-5085(98)70537-2.
Results Reference
background
PubMed Identifier
10655248
Citation
Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mossner J. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology. 2000 Feb;31(2):291-8. doi: 10.1002/hep.510310205.
Results Reference
background
PubMed Identifier
19455276
Citation
Gao F, Bai Y, Ma SR, Liu F, Li ZS. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010 Mar;17(2):125-31. doi: 10.1007/s00534-009-0109-3. Epub 2009 May 20.
Results Reference
background
PubMed Identifier
16279895
Citation
Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005 Nov;100(11):2426-30. doi: 10.1111/j.1572-0241.2005.00318.x.
Results Reference
background
PubMed Identifier
14598251
Citation
Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mossner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003 Nov;125(5):1355-63. doi: 10.1016/j.gastro.2003.07.015.
Results Reference
background
PubMed Identifier
28405328
Citation
Dolak W, Schwaighofer H, Hellmich B, Stadler B, Spaun G, Plieschnegger W, Hebenstreit A, Weber-Eibel J, Siebert F, Emmanuel K, Knoflach P, Gschwantler M, Vogel W, Trauner M, Puspok A; Austrian PDT study group. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. United European Gastroenterol J. 2017 Feb;5(1):104-110. doi: 10.1177/2050640616654037. Epub 2016 Jul 7.
Results Reference
derived
Learn more about this trial
Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction
We'll reach out to this number within 24 hrs